Elan Reports Mixed Alzheimer Results

Elan(ELN Quote) and Wyeth(WYE Quote) reported mixed results from a midstage test of bapineuzumab in patients with Alzheimer's disease Tuesday.

Overall, bapineuzumab conferred no statistically significant benefit on the 240 patients enrolled in the phase II study. However, the drug was at least partially effective in a subgroup of patients lacking a higher genetic risk for developing Alzheimer's, the companies said Tuesday.

Based on these overall results, Elan and Wyeth said the ongoing phase III clinical trials of bapineuzumab will continue, although the companies did not say whether changes would be made to these studies. ...